Total Payments
$203,793
2024 Payments
$28,934
Companies
98
Transactions
2,139
Medicare Patients
3,345
Medicare Billing
$830,751
Payment Breakdown by Category
Other$128,070 (62.8%)
Food & Beverage$35,260 (17.3%)
Consulting$27,970 (13.7%)
Travel$12,240 (6.0%)
Education$252.74 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $115,070 | 81 | 56.5% |
| Food and Beverage | $35,260 | 1,942 | 17.3% |
| Consulting Fee | $27,970 | 15 | 13.7% |
| Honoraria | $13,000 | 6 | 6.4% |
| Travel and Lodging | $12,240 | 91 | 6.0% |
| Education | $252.74 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $99,092 | 212 | $0 (2024) |
| Lilly USA, LLC | $52,640 | 171 | $0 (2024) |
| ARGENX US, INC. | $21,626 | 45 | $0 (2024) |
| Amgen Inc. | $3,256 | 63 | $0 (2024) |
| ABBVIE INC. | $2,454 | 138 | $0 (2024) |
| Allergan, Inc. | $1,707 | 111 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $1,632 | 121 | $0 (2024) |
| UCB, Inc. | $1,434 | 59 | $0 (2024) |
| Lundbeck LLC | $1,304 | 69 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,292 | 97 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,934 | 234 | Alexion Pharmaceuticals, Inc. ($13,446) |
| 2023 | $26,092 | 238 | Alexion Pharmaceuticals, Inc. ($11,726) |
| 2022 | $12,247 | 204 | Alexion Pharmaceuticals, Inc. ($7,497) |
| 2021 | $11,480 | 229 | Alexion Pharmaceuticals, Inc. ($5,614) |
| 2020 | $27,720 | 233 | Lilly USA, LLC ($13,461) |
| 2019 | $54,800 | 389 | Alexion Pharmaceuticals, Inc. ($28,768) |
| 2018 | $28,066 | 279 | Alexion Pharmaceuticals, Inc. ($16,210) |
| 2017 | $14,455 | 333 | Lilly USA, LLC ($5,454) |
All Payment Transactions
2,139 individual payment records from CMS Open Payments — Page 1 of 86
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: EPILEPSY | ||||||
| 12/16/2024 | Cycle Pharmaceuticals Inc | Ormalvi (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $29.46 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $8.90 | General |
| Category: PAIN | ||||||
| 12/10/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $38.73 | General |
| Category: Neuroscience | ||||||
| 12/10/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Neurology | ||||||
| 12/06/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/04/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Immunology | ||||||
| 11/27/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.78 | General |
| Category: NEUROLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: PAIN | ||||||
| 11/21/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 11/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: Immune | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $28.96 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $10.37 | General |
| Category: Rare Disease | ||||||
| 11/14/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 11/14/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $4.92 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 11/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $11.01 | General |
| Category: NEUROLOGY | ||||||
| 11/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $8.27 | General |
| Category: PAIN | ||||||
| 11/11/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: Analgesic | ||||||
| 11/08/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 11/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $3.24 | General |
| Category: BOTOX THERAPEUTIC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 794 | 28,304 | $737,322 | $219,815 |
| 2022 | 18 | 873 | 25,084 | $770,787 | $214,258 |
| 2021 | 17 | 876 | 22,762 | $732,510 | $204,039 |
| 2020 | 17 | 802 | 24,206 | $709,868 | $192,639 |
Total Patients
3,345
Total Services
100,356
Medicare Billing
$830,751
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 42 | 26,750 | $267,500 | $126,546 | 47.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 140 | 209 | $114,950 | $18,087 | 15.7% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2023 | 83 | 601 | $24,040 | $15,165 | 63.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 34 | 96 | $76,800 | $10,313 | 13.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 80 | 125 | $37,500 | $7,798 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 53 | $35,775 | $7,127 | 19.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 41 | 72 | $28,800 | $5,734 | 19.9% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2023 | 53 | 56 | $26,582 | $5,201 | 19.6% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2023 | 72 | 78 | $19,344 | $4,976 | 25.7% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2023 | 83 | 90 | $30,385 | $3,197 | 10.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 22 | $7,304 | $3,018 | 41.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $14,250 | $2,872 | 20.2% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 20 | 20 | $22,000 | $2,808 | 12.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 26 | 66 | $14,850 | $2,589 | 17.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 19 | $3,192 | $1,788 | 56.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $10,200 | $1,696 | 16.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $3,850 | $898.40 | 23.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 33 | 23,200 | $232,000 | $109,177 | 47.1% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2022 | 102 | 896 | $35,840 | $23,326 | 65.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 142 | 198 | $108,900 | $18,325 | 16.8% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 23 | 74 | $59,200 | $7,617 | 12.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 85 | 117 | $35,100 | $7,568 | 21.6% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2022 | 68 | 78 | $54,288 | $7,457 | 13.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 46 | 57 | $38,475 | $7,420 | 19.3% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2022 | 76 | 84 | $20,832 | $5,530 | 26.5% |
About Dr. Jeffrey Tamsing, M.D
Dr. Jeffrey Tamsing, M.D is a Neurology healthcare provider based in Parker, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1457518680.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Tamsing, M.D has received a total of $203,793 in payments from pharmaceutical and medical device companies, with $28,934 received in 2024. These payments were reported across 2,139 transactions from 98 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($115,070).
As a Medicare-enrolled provider, Tamsing has provided services to 3,345 Medicare beneficiaries, totaling 100,356 services with total Medicare billing of $830,751. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Parker, CO
- Active Since 05/16/2008
- Last Updated 04/22/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1457518680
Products in Payments
- SOLIRIS (Drug) $44,660
- ULTOMIRIS (Biological) $30,824
- EMGALITY (Drug) $25,334
- VYVGART (Drug) $17,179
- Soliris (Drug) $15,748
- VYVGART HYTRULO (Drug) $3,021
- REYVOW (Drug) $2,275
- UPLIZNA (Biological) $2,200
- BOTOX (Biological) $1,505
- ZEPOSIA (Drug) $1,162
- UBRELVY (Drug) $1,124
- TROKENDI XR (Drug) $1,013
- Aimovig (Biological) $958.25
- INGREZZA (Drug) $830.60
- NURTEC ODT (Drug) $759.02
- AUBAGIO (Drug) $735.45
- RADICAVA (Drug) $731.28
- VYEPTI (Biological) $721.11
- QULIPTA (Drug) $693.52
- SOLIRIS (Biological) $564.34
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.